UK Companies House feature
TEVA PHARMA HOLDINGS LIMITED
Profile
- Company number
- 10119709
- Status
- Active
- Incorporation
- 2016-04-12
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Subsidiaries
- Arrow Generics Limited · 100% held · United Kingdom · Dormant company
- Breath Limited · 100% held · United Kingdom · License holder company
- Cephalon (UK) Limited · 100% held · United Kingdom · Dormant company
- Norton Healthcare Limited · 100% held · United Kingdom · Research, development and manufacture of pharmaceutical products
- Pliva Pharma Limited · 100% held · United Kingdom · Dormant company
- Teva Laboratories UK Limited · 100% held · United Kingdom · License holder company
- Teva Pharmaceuticals Limited · 100% held · United Kingdom · Dormant company
- Teva UK Limited · 100% held · United Kingdom · Marketing and distribution of pharmaceutical products
- Teva UK Holdings Limited · 100% held · United Kingdom · Dormant company
Significant events
- “On 5 November 2024 the company's directly owned subsidiary, Teva UK Holdings Limited, transferred its fully-owned subsidiaries Cephalon (UK) Limited, Norton Healthcare Limited, Pliva Pharma Limited, Teva Pharmaceuticals Limited and Teva UK Limited to the company.”
- “The company's previously dormant subsidiaries, Arrow No 7 Limited and Bowmed Limited were dissolved on 2 December 2024.”
- “On 29 February 2024, the company reduced its share capital from £311,983,396 to £1 and transferred the realised reserve thereby arising to profit and loss account reserves.”
- “On the same date, the company received a dividend of £152,786,000 (2023: £nil) from Teva UK Holdings Limited, which was partially used by the company to repay the total of the amounts due to a fellow group undertaking, Teva Finance Services II B.V. (TFS II), under a revolving credit agreement with the remainder transferred to the company's deposit agreement with TFS II.”
- “On 3 April 2024, the company entered into a series of intra-group transactions to simplify a number of intercompany balances within the company and the wider group, and this had the effect on Teva Pharma Holdings Limited as described below...”
- “On 19 November 2024, the company received dividends of £58,000,000 and £94,000,000 from Teva UK Limited and Teva Laboratories UK Limited respectively.”
- “On 19 March 2025, the company's wholly-owned direct subsidiary company, Piva Pharma Limited, assigned a receivable balance of £4,905,000 owed by a fellow group undertaking, Teva UK Limited, to the company, in consideration for an interest-free receivable of the same amount.”
- “Thereafter on the same date, Teva UK Limited settled the £9,589,000 amount that it owed to the company resulting from the above transactions, and then a dividend of £9,589,000 was paid by the company to its immediate parent company, Teva Pharmaceuticals Europe B.V. (TPE), representing an amount of £9,589,000/share.”
- “Following these transactions, the directors concluded that the carrying amount of the company's investment in Pliva Pharma Limited exceeded its recoverable amount and therefore an impairment charge of £224,000 was recognised.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
2 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| INNES, Kim | Director | 2016-09-27 | Aug 1968 | British |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| PINSENT MASONS SECRETARIAL LIMITED | Corporate Secretary | 2017-03-13 | 2017-03-13 |
| COOPER, Dean Michael | Director | 2018-07-12 | 2020-04-29 |
| DANIELL, Richard Gordon | Director | 2016-04-12 | 2016-09-27 |
| SCHREWE, Michael | Director | 2016-04-12 | 2016-08-01 |
| VRHOVEC, David | Director | 2016-05-01 | 2026-01-01 |
| WILLIAMS, Robert | Director | 2016-04-12 | 2018-06-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Pharmaceuticals Industries Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-12 | Active |
Filing timeline
Last 20 of 42 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-04-13 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2026-01-05 | TM01 | officers | termination director company with name termination date |
| 2025-10-06 | AA | accounts | accounts with accounts type full |
| 2025-04-14 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-08-08 | AA | accounts | accounts with accounts type full |
| 2024-04-11 | CS01 | confirmation-statement | confirmation statement with updates |
| 2024-03-12 | SH19 | capital | capital statement capital company with date currency figure |
| 2024-03-06 | SH20 | capital | legacy |
| 2024-03-06 | CAP-SS | insolvency | legacy |
| 2024-03-06 | RESOLUTIONS | resolution | resolution |
| 2023-08-07 | AA | accounts | accounts with accounts type full |
| 2023-04-11 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-09-26 | AA | accounts | accounts with accounts type full |
| 2022-04-11 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-10-03 | AA | accounts | accounts with accounts type full |
| 2021-04-27 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-04-15 | CH01 | officers | change person director company with change date |
| 2021-04-15 | CH01 | officers | change person director company with change date |
| 2020-11-09 | AA | accounts | accounts with accounts type full |
| 2020-04-29 | TM01 | officers | termination director company with name termination date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.